Literature DB >> 11902989

Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review.

Gudula Kirtschig1, Dédée Murrell, Fenella Wojnarowska, Nonhlanhla Khumalo.   

Abstract

OBJECTIVE: To identify and critically evaluate evidence from randomized controlled trials for the efficacy of treatments for mucous membrane pemphigoid (MMP)/cicatricial pemphigoid (CP) and epidermolysis bullosa acquisita (EBA). SEARCH STRATEGY: Review of MEDLINE from 1966 through March 2000, EMBASE from 1980 through March 2000, and the Cochrane Controlled Trials Register (February 28, 2001) to identify randomized controlled trials for the efficacy of treatments in MMP/CP and EBA. SELECTION CRITERIA: All randomized controlled trials of therapeutic interventions that included patients with MMP/CP or EBA confirmed by immunofluorescence study findings. All age groups were included.
RESULTS: We found 2 small randomized controlled trials of MMP/CP, both conducted in patients with severe eye involvement. We were not able to identify a randomized controlled trial of therapeutic interventions in EBA.
CONCLUSIONS: There is evidence from 2 small trials that severe ocular CP responds best to treatment with cyclophosphamide, and mild to moderate disease seems effectively suppressed by treatment with dapsone. No treatment recommendations can be made for EBA because to our knowledge no randomized controlled trials are published. Even though systemic corticosteroids are regarded as the gold standard in the treatment of MMP/CP and EBA, there is poor evidence from the literature that they are the best treatment for these diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11902989     DOI: 10.1001/archderm.138.3.380

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  17 in total

Review 1.  Epidermolysis bullosa acquisita.

Authors:  Rishu Gupta; David T Woodley; Mei Chen
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 2.  Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.

Authors:  Mei Chen; Gene H Kim; Lori Prakash; David T Woodley
Journal:  Autoimmunity       Date:  2011-09-28       Impact factor: 2.815

Review 3.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  [Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab].

Authors:  A Recke; I Shimanovich; P Steven; L Westermann; D Zillikens; E Schmidt
Journal:  Hautarzt       Date:  2011-11       Impact factor: 0.751

Review 5.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

Review 6.  Dapsone in the management of autoimmune bullous diseases.

Authors:  Evan W Piette; Victoria P Werth
Journal:  Dermatol Clin       Date:  2011-10       Impact factor: 3.478

Review 7.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Pharmacotherapy of scleritis: current paradigms and future directions.

Authors:  Robert M Beardsley; Eric B Suhler; James T Rosenbaum; Phoebe Lin
Journal:  Expert Opin Pharmacother       Date:  2013-02-21       Impact factor: 3.889

9.  Cyclophosphamide for ocular inflammatory diseases.

Authors:  Siddharth S Pujari; John H Kempen; Craig W Newcomb; Sapna Gangaputra; Ebenezer Daniel; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; C Stephen Foster
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

Review 10.  [Optimizing therapy in patients with severe autoimmune blistering skin diseases].

Authors:  E Schmidt
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.